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Corynebacterium acnes strains cross-resistant to clin-
damycin and erythromycin were observed following 
long-term selection or mutagenic treatment in the labo-
ratory. Similar strains were found among clinical iso-
lates from patients using clindamycin or erythromycin 
topically in the treatment of acne vulgaris. Clindamycin 
resistance was never observed in the absence of resist-
ance to macrolides or other lincosaminides. It is sug-
gested that this resistance may result from an alteration 
of the 50S ribosomal subunit. 
Clindamycin is a lincosaminide antibiotic which has been 
shown to be effective in the treatment of acne vulgaris, probably 
through its antibacterial action against Corynebacterium 
acnes· [1]. The effectiveness of clindamycin might be dimin-
ished if C. acnes developed resistance to it. 
We began a search for clindamycin-resistant strains of C. 
acnes to ascertain their prevalence and clinical importance and, 
if possible, to study the mechanism of their resistance. Four 
different approaches were taken in the search for resistant 
strains: (1) Exposing a wild type C. acnes strain to clindamycin 
to see how readily spontaneous resistance occurs in the labo-
ratory, (2) applying stepwise selective pressure by transfening 
a wild type strain into increasing levels of clindamycin, (3) 
exposing a growing culture to a mutagen to induce resistant 
mutants, and (4) isolating C. acnes strains from patients who 
h ad been treating themselves topically with clindamycin and 
searching for resistant strains among these isolates. 
Sugar fermentation, gel liquefaction, production of indole and 
agglutination by specific antisera were used to characterize the 
strains used in this study. Strains were also tested for sensitivity 
to ampicillin, bacitracin, kanamycin, neomycin, lincomycin, 
erythromycin, oleandomycin, streptomycin, penicillin, and tet-
racycline. 
MATERIALS AND METHODS 
lsolation of Strains 
The wild type strain and the clinical isolates were obtained from 
open comedones. The area to be sampled was wiped with 70% isopropyl 
alcohol and the comedo expressed with a Schamberg comedo extractor. 
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The contents were emulsified in sterile Triton-X phosphate buffer 
(0.067 M Na2HPO" 0.067 M KH2PO., 0.05% Triton-Xloo, pH 7.9) 
diluted, and streaked onto Brain Heart Infusion agar (BHIA) (Difco) 
plates. After incubation anaerobically for 3- 4 days at 37°C, presumptive 
C. acnes colonies were identified by their small size «1 mm) and beige 
to pinkish-beige color. Verification was by Gram stain. Cultures were 
maintained in thioglycollate broth tubes (Difco) with I % Tween 80, 
incubated aerobically at 37°C and transferred every 4- 5 days. 
Antibiotic Tests 
Antibiotic sensitivity tests were made by inoculating 0.1 ml of a 
growing cultUTe into sterile thioglycollate broth tubes containing the 
desired concentration of antibiotic. Tubes were inspected after 2 and 7 
days for signs of growth. Clindamycin sensitivity was also tested on 
BHIA plates by adding the desired concentration of the antibiotic to 
the agar before autoclaving (clindamycin is stable to autoclaving at 
neutral pH) and spreading 0.1 ml of a growing culture onto the plates. 
Antibiotic disc tests were done by spreading a lawn of cells (0.1 ml) 
onto a BHIA plate and placing an antibiotic disc in the center of the 
plate. All plates were incubated in anaerobic jars (Gas Pak-Baltimore 
Biological Laboratories) for 4 days. Discs that were prepared by us 
utilized blank paper discs (QBBL-Becton Dickinson & Co., Cockeys-
ville, Maryland) 0.25 inches in diameter which were dipped into differ-
ent concentrations of clindamycin HCL or erythromycin base. The 
solvent for the antibiotics was 30% M-pyrol in 70% isopropyl alcohol. 
The discs were air dried before use. All antibiotic solutions were 
prepared within 2 days of use in the experiments. 
Selection Experiment 
A tube containing 10 ml of thioglycollate broth plus 0.01 Jig/ ml 
clindarnycin was inoculated with 0.1 ml of a growing wild type culture. 
Cells which grew in the 0.01 Jig/ml tube served as inoculum (0.1 ml) for 
tubes containg higher levels of clindarnycin (0.025, 0.04 and 0.05 Jig/ 
ml). Cells from the last tube to show growth were then transferred into 
tubes containing still higher levels of clindamycin. Thus, resistance was 
selected for by exposing the wild type strain to gradually increasing 
c1indamycin concentrations. 
Mutagenesis 
N-methyl-N'-nitro-N-nitrosoguanidine (NTG) was added to a wild 
type culture growing exponentially in 3 ml of thioglycollate broth. In 
various experiments NTG concentrations from 30- 300 Ilg/ml and ex-
posure times of 15 to 40 min were used. A control tube to which no 
NTG was added was included in each experiment. After treatment the 
cells were centrifuged, washed with 10 ml of sterile TM buffer (prepared 
according to [2] with bis-tris-propane (Sigma) substituted for 2-amino-
2-(hydroxymethyl)-1,3-propanediol), and resuspended to 10 ml of fresh 
thioglycollate broth. Viable cell counts were done on BHIA plates 
immediately after resuspension in broth to ascertain the percentage of 
cells killed. Treated cells were then incubated for 1-2 days before being 
spread (0.1 ml) on c1indamycin-containing BHIA plates to detect re-
sistant mutants. . 
Biochemical Tests 
Carbohydrate utilization tests were done in thioglycollate broth 
containing 0.05% bromophenol blue but without dextrose or resazurin. 
Glycerol, D-glucose, D-mannose, D-galactose, lactose, maltose, glyco-
gen, D-fructose and sucrose were added to the tubes in a final concen-
tration of 1%. Fermentation was detected by the development of a 
yellow color in the tube. 
Gelatin liquefaction was determined by Frazier's precipitation 
method [3]. The center of a gelatin agar plate was inoculated with 0.05 
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ml of a. suspension of C. acnes. After 7 days of anaerobic incubation, 
the pla te was flooded with acidic HgCh. 
Indole production was tested in tryptose yeast extract glucose thio· 
glycollate broth [4]. Indole was extracted from the medium with toluene 
and detected with indole reagent. 
S erological Tests 
Commercial C. acnes antisera numbers 554 and 605 (Difco) were 
used to agglutinate washed cell suspensions in slide agglutination tests. 
Agglutination in one or both antisera in the absence of agglutination in 
a saline control constituted a positive C. acnes identification. 
All clinical samples from acne patients were comedones taken with 
a Schamberg comedo extractor and processed as reported in a previous 
communication [1]. The clinical samples from patients 1-10 in T able I 
were tested on agar into which clindamycin HCl was incorporated in 
different concentrations. Subsequent isolates were tested as effectively 
and more conveniently by observing the lowest of 5 concentrations of 
clindamycin discs causing clear inhibition of growth in the disc inhibi· 
tion test. T he solutions into which the discs were immersed before a ir 
drying were 1.0,0.1,0.01,0.001 and 0.0001 percent clindamycin. 
RESULTS 
The minimum concentration of clindamycin completely in-
hibiting growth of wild type C. acnes is about 0.1 !!g/mi in 
thioglycollate broth and about 0.02 !!g/ mi in BHIA plates. 
Resistance of individual wild type cells varied, with some cells 
sensitive to much lower levels of the antibiotic. No wild type 
cells were ever found to be resistant to clindamycin at 1 !!g/ mi 
in broth. 
The selection experiment produced a strain (SI) resistant to 
more than 100 times the concentration of clindamycin com-
pletely inhibitory to the wild type. This level of resistance was 
very slow to develop, however. Early in the experiment resist-
ance increased by only about 0.05 !!g/ mi at each transfer. As 
the culture became more resistant it was able to tolerate greater 
increases in clindamycin concentration. Twelve transfers were 
required to produce S1. 
The mutagenesis experiment was performed to see if resist-
ance could be developed by mutation in a single step. Mutagen-
esis was attempted in 12 experiments using several concentra-
tions of nitrosoguanidine for varying exposure times. Only one 
TABLE 1. Sensitivity of C. acnes isolated from comedones of patients 
using 1% topical clindamycin lotion 
Minimal inhibitory clindamycin 
Patient . Time on concentration 
No. Sex clindamycin lotion In BHIA" agar In discs (l'g/rnI) (% solution) / 
1 F 2 mo 0.1 
2 F 2yr NR' 
3 (Rl) F 6 mo >20.0 
4 F 3 yr NR 
5 (R2) F 2 yr >20.0 
6 F 1 yr 0.01 
7 F 9 mo 0.15 
8 F 4 rno 0.05 
9 M 4 mo 0.15 
10 F 2 mo NR 
11 F 4 mo NR 
12 F 12 mo 10 
13. F 10 mo 0.001 
14 M 4 mo NR 
15 F 4 mo NR 
16 F 10 mo 10 
17 M 5 mo 0.001 
18 F 1 yr NR 
19 F 2 mo 0.01 
20 M Many mo 0.01 
21 F 4 mo 0.01 
22 M 4 mo NR 
" BHIA = brain heart infusion agar. 
/, Blank discs immersed in solu t ion and then air dried before use. 
e NR = No C. acnes recovered from comedones. 
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TABLE II. Sensitivity of C. acnes isolated from comedones of 
patients using 1% topical erythromycin lotion 
Time on Minimum inhibitory concentration Patient Sex erytl'lfomycin of discs" No. lotion Erythromycin Clindamycin 
1 F 8 weeks 1.0 1.0 
2 F 8 weeks 0.01 0.001 
3 M 8 weeks 0.001 0.001 
4 F 8 weeks 0.01 0.01 
5 M 8 weeks 1.0 1.0 
6 F 8 weeks 0.001 0.001 
7 F 8 weeks 0.01 0.01 
8 M 8 weeks 0.01 0.001 
9 M 8 weeks 1.0 1.0 
10 F 8 weeks 0.001 0.001 
11 F 8 weeks 1.0 1.0 
12 F 8 weeks 0.01 0.01 
13 M 8 weeks 0.01 0.001 
14 F 8 weeks 0.001 0.001 
15 F 8 weeks 0.001 0.001 
16 M 8 weeks 0.01 0.001 
17 F 8 weeks NR" NR 
18 F 8 weeks 0.01 0.001 
19 F 8 weeks NR NR 
20 M 8 weeks 0.001 0.001 
21 F 8 weeks 0.001 0.001 
" Blank discs immersed in solution and air dried before use. Antibiotic 
discs made from solutions of 5 different concentrations (1.0, 0.1, 0.01, 
0.001 and 0.0001 percent) of antibiotic. 
/, NR = No C. acnes recovered from comedones. 
resistant mutant (Ml) was obtained in these experiments. M1 
came from a C. acnes culture which had been treated with 100 
!!g/mi of nitrosoguanidine for 15 min. This treatment killed 26% 
of the cells in the culture. Ml proved to be resistant to high 
levels of both clindamycin and erythromycin, but at high clin-
damycin levels it grew somewhat more slowly than S1. Similar 
erythromycin levels did not inhibit its growth. 
The third method of obtaining clindamycin resistant C. acnes 
was by isolation from comedo saJ;Tlples taken from patients 
treating themselves topically with clindamycin for over 4 
months. Of 22 patients tested, 5 gave rise to strains showing 
resistance to high levels of clindamycin and one had a strain 
which possessed intermediate resistance (Table I). Comedo 
samples were also taken from 21 patients on topical 1 % eryth-
romycin lotion for acne vulgaris for 8 weeks. From 4 of the 21 
subjects C. acnes resistant to erythromycin was isolated. The 
level of resistance observed allowed growth on agar plates next 
to discs saturated with erythromycin at 10 mg/ mi. All these 
organisms resistant to erythromycin were also resistant to com-
parable levels of clindamycin (Table II). 
Representative strains from each type of experiment (selec-
tion, mutation and clinical isolation) were tested for biochemical 
properties, specific antiserum agglutination and antibiotic sen-
sitivity. Results are shown in Table III and Table IV. The 
strains were identical biochemically and only slight differences 
were noted in antibiotic sensitivity. On the basis of the bio-
chemical tests, all strains used in this study seem to be of the 
type designated C. acnes Group I (Propionibacterium acnes) 
by Voss [5]. 
DISCUSSION 
Clindamycin, lincomycin and the macrolide antibiotics tested 
in this study act by binding to the 50S ribosomal subunit and 
inhibiting protein synthesis. By analogy with other inhibitors, 
resistance to such antibiotics could be due to (1) synthesis of an 
enzyme capable of inactivating the antibiotic, (2) prevention of 
access of the antibiotic to the ribosome, or (3) modification of 
the ribosomes so they become insensitive to the antibiotic. The 
data derived from this study are not sufficient to define the 
type of resistance found in C. acnes. However, the results 
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TABLE III. Characterization of wild type and resistant strains of C. acnes 
Antiserum Biochemical Tests Antibiotic Disc" Sensitivities agglutination 
Strain Source (mm of inhibi· 
554 605 Sugars Indole Gelatin Lincomycin tion) Oleandomycin fermented" production liquefaction Erythromycin 
Wild type Comedo (normal)" + + Glu, Man, Gly, + + 18 29 19 
Fru, Gal 
SI Selection + + Glu, Man, Gly, + + 0 0 0 
Fru, Gal 
MI Mutation + + Glu, Man, Gly, + + 0 0 0 
Fru, Gal 
Rl Comedo (patient)" + + Glu, Man, Gly, + + 0 0 0 
Fru, Gal 
R2 Comedo (patient)" + + Glu, Man, Gly, + + 0 0 0 
Fru, Gal 
" Abbreviations: Glu, D-Glucose; Man, D-Mannose; Gly, Glycerol; Fru, D-Fructose; Gal, D-Galactose. Fermentation tests required 4-12 days 
to become positive and were considered negative after 14 days. 
/, Discs contained 2 f.Lg of the antibiotic. 
,. Normal subject- no topical or systemic antibiotics. 
d Patients with acne treated for over 6 mo with topical c1indamycin 1% solu tion. 
TABLE IV. Antibiotic sensitivity of wild type and resistant strains of C. acnes 
Minimal inhibitory concentration" in thioglycollate broth 
Strain Source Chnda- Erythro- Tetra- Baci- Ampi- Peni- Strepto- Kana- Neo-
mycin mycm cycline tracin cillin cillin mycin mycin mycin 
Wild type Comedo 0.10 0.125 2-3 0.5-1 0.3-0.5 0.1-0.3 50-70 100-200 100-200 
Sl Selection >20 >20 1-2 0.3-0.5 0.3-0.5 0.1-0.2 25-50 100-200 100-200 
Ml Mutation >20 >20 1-2 0.1-0.3 0.2-0.4 0.1-0.3 25-60 100-200 50-100 
Rl Comedo (patient) >20 >20 1-2 0.5-1.0 0.3-0.5 0.5-0.7 50-75 100-200 50-100 
R2 Comedo (patient) >20 >20 5 0.3-0.5 0.5-1.0 0.7-1.0 50-75 100-200 50-100 
" Concentrations (f.Lg/ml except for bacitracin and penicillin which are in units/ mil showing little or no growth after 7 days. 
described, and some additional experiments which were per-
formed, provide some clues to the probable mechanism. 
In an attempt to detect the presence of an enzyme capable of 
inactivating clindamycin, resistant strains were streaked on one 
half of clindamycin-containing BHIA plates and the sensitive 
wild type strain was streaked on the other half. Concentrations 
of clindamycin near the minimal inhibitory level were chosen. 
If an inactivating enzyme not frrmly bound to the cell were 
being produced, it might diffuse out from the resistant orga-
nisms and permit growth of the sensitive strain. However, none 
of the plates showed growth of sensitive organisms adjacent to 
the resistant strain. 
A second attempt to detect the presence of an inactivating 
enzyme involved inoculating sensitive cells into clindamycin-
containing thioglycollate broth which had previously supported 
the growth of resistant organisms. The spent medium was 
sterilized by filtration and mixed with fresh sterile thioglycollate 
broth before inoculation with the sensitive strain. Sensitive 
organisms could grow in this medium only if the clindamycin 
had been inactivated by the growth of resistant cells. No 
indication of clindamycin inactivation was obtained. 
Resistance due to prevention of access of the antibiotic to 
the ribosome is possible, but seems unlikely because of the 
demonstrated cross-resistance to 2 different classes of antibi-
otics, lincosaminides and macrolides. It seems improbable that 
transport of 2 such dissimilar compounds to the interior of the 
cell should be impeded without affecting passage of other 
antibotics and compounds necessary for cell growth. 
A more likely mechanism of resistance that might account 
for macrolide and lincosaminide cross-resistance involves a 
change in some component of the 50S ribosomal subunit. Weis-
blum and Demohn [6] described a ribosomal modification in 
Staphylococcus aureus which gives resistance to macrolides 
and lincosaminides but not to other 50S ribosomal inhibitors or 
to antibiotics acting elsewhere. This mechanism involves an 
alteration of the 23S rRNA induced by low levels of erythro-
mycin. Presumably this change in the 23S rRNA prevents 
lincosaminides and macrolides from binding to the 50S ribo-
somal subunit but allows the ribosome to remain functional. 
The fact that other 50S ribosomal inhibitors are still effective 
suggests that lincosaminides and macrolides share at least part 
of a common binding site on the 50S subunit. 
In a search for induced resistance in C. acnes similar to that 
described in S. aures [7], cells were grown in tubes containing 
subinhibitory levels of erythromycin and subsequently tested 
for resistance to higher levels of erythromycin or to clindamy-
cin. Antibiotic-containing discs were also used to test for induc-
tion. Erythromycin discs were placed near discs containing 
other macrolides or lincosaminides. A decreased radius of in-
hibition by lincosaminides or other macrolides in the areas near 
the erythromycin disc would suggest induced resistance [6, 7). 
No evidence for induction was found with either of these 
methods. 
Though the mechanism of clindamycin resistance in C. acnes 
is probably not an inducible (or constitutive) alteration in the 
23S rRNA, a change in the 50S ribosomal subunit could still 
account for the cross-resistance observed in this study. Tanaka 
et al [8] described an erythromycin resistant mutant of Esche-
richia coli having an altered 50S ribosomal protein and a 
reduced ability to bind erythromycin. Teraoka, Tamaki, and 
Tanaka [9] found this erythromycin-resistant strain to be less 
active in protein synthesis than the wild type. Tanaka et al [10] 
demonstrated that resistance to erythromycin was always ac-
companied by cross-resistance to other macrolide antibiotics. 
The possibility of an altered ribosomal protein in C. acnes 
conferring resistance to macrolide and lincosaminide antibiotics 
is compatible with all the data obtained in this study. If indeed 
lincosaminide and macrolide antibiotics share a common or 
overlapping binding sites, then cross-resistance to the clinda-
mycin-resistant variants could be due to a mutant ribosomal 
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protein. Resistant strains, especially those developed through 
selection in the laboratory, were found to be somewhat slower 
growing in antibiotic-free media than sensitive strains. Clinda-
mycin-resistant strains induced in the laboratory were also 
more sensitive to some nonmacrolide antibiotics than wild type 
strains (Table IV) . Both of these observations could be due to 
an impairment in the protein synthesizing efficiency of resistant 
ribosomes. 
The fact that the single-step resistant mutant Ml showed a 
growth rate inhibition by clindamycin could be explained by a 
slight change in ribosomal protein structure sufficient to lessen 
but not completely destroy the affinity of clindamycin for the 
ribosomal binding site. Perhaps more than a single amino acid 
change is necessary to alter the site enough to prevent clinda-
mycin binding entirely. Interestingly, the rate of growth of 
strain Ml is normal in the presence of erythromycin and other 
macrolides. This may indicate that the binding sites for clin-
damycin (lincosaminides) and erythromycin (macrolides) are 
not identical. 
In the clinical use of topical clindamycin and erythromycin 
there is evidence for resistant C. acnes organisms developing in 
about 20% of the subjects. When organisms become resistant to 
1 of these 2 antibiotics they develop resistance to the other 
antibiotic at the same time. We have preliminary evidence that 
normally sensitive strains of C. acnes return and take over the 
comedones if topical clindamycin or erythromycin lotions are 
stopped for 1-2 mo. 
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